Nanopass Technologies Ltd.

NanoPass Technologies Ltd. is a commercial-stage company focused on developing advanced intradermal delivery solutions for vaccines and drugs. Utilizing Micro Electro Mechanical Systems (MEMS) technology, NanoPass creates precise and efficient delivery devices that aim to improve patient care worldwide. The company is recognized as a pioneer in this field and is ISO13485 certified. The flagship product, MicronJet™, is a 0.6mm hollow microneedle device that has received FDA clearance for intradermal delivery. Its unique design ensures mechanical stability and allows for consistent, painless delivery of substances approved for skin administration. NanoPass's technology enhances the administration of vaccines and drugs, making the process less painful and more efficient, with applications in both immunology and medical aesthetics. NanoPass targets pharmaceutical companies and distributors globally, aiming to expand the availability of its innovative delivery solutions. The company is supported by strategic partners and venture capitalists, which bolsters its efforts in enhancing healthcare delivery standards.

• Employees 20
• Founded 2000
• Annual Revenue $8000000
• Total Funding $4000000